within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE05_Amprenavir;

model Amprenavir
  extends Pharmacolibrary.Drugs.ATC.J.J05AE05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AE05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Amprenavir is a protease inhibitor antiretroviral drug used for the treatment of HIV infection. It was approved for use in combination with other antiretroviral agents for the management of HIV-1 infection in adults and pediatric patients. However, amprenavir has been discontinued in many countries and replaced by more potent protease inhibitors with better pharmacokinetic profiles.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in healthy adult volunteers (both sexes) after single oral dose administration.</p><h4>References</h4><ol><li><p>Foster, RH, &amp; Faulds, D (1998). Abacavir. <i>Drugs</i> 55(5) 729–738. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199855050-00018&quot;>10.2165/00003495-199855050-00018</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9585869/&quot;>https://pubmed.ncbi.nlm.nih.gov/9585869</a></p></li><li><p>Sadler, BM, &amp; Stein, DS (2002). Clinical pharmacology and pharmacokinetics of amprenavir. <i>The Annals of pharmacotherapy</i> 36(1) 102–118. DOI:<a href=&quot;https://doi.org/10.1345/aph.10423&quot;>10.1345/aph.10423</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11816239/&quot;>https://pubmed.ncbi.nlm.nih.gov/11816239</a></p></li><li><p>Sadler, BM, et al., &amp; Stein, DS (2001). Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects. <i>Journal of clinical pharmacology</i> 41(4) 386–396. DOI:<a href=&quot;https://doi.org/10.1177/00912700122010249&quot;>10.1177/00912700122010249</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11304895/&quot;>https://pubmed.ncbi.nlm.nih.gov/11304895</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Amprenavir;
